CKPT News and Press, Checkpoint Therapeutics Inc. From 12/18/23

2023-12-18 10:28:27 ET Shares of Checkpoint Therapeutics ( NASDAQ: CKPT ) plunged 50% in morning trading Monday after the company said the FDA had declined to approve its drug cosibelimab for the treatment of advanced cutaneous squamous cell carcinoma, a common type of skin cancer. ...

WALTHAM, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for the cosibelimab biologic li...

2023-12-11 12:26:14 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some of the most explosive opportunities can be found in biotech stocks. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example. Leading up to U.S. FDA rulings, the st...

2023-12-06 14:48:10 ET Penny Stocks – How News Makes These Small Caps Soar or Plunge Penny stocks , securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks require...

Upcoming PDUFA goal date of January 3, 2024 U.S. patent protection for cosibelimab through at least May 2038 WALTHAM, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted onc...

2023-11-17 17:49:49 ET More on Checkpoint Therapeutics Seeking Alpha’s Quant Rating on Checkpoint Therapeutics Historical earnings data for Checkpoint Therapeutics Financial information for Checkpoint Therapeutics For further details see: Checkpoin...

Checkpoint Therapeutics Inc. (CKPT) is expected to report $-0.85 for Q3 2023

2023-11-14 01:33:18 ET More on Checkpoint Therapeutics Seeking Alpha’s Quant Rating on Checkpoint Therapeutics Historical earnings data for Checkpoint Therapeutics Financial information for Checkpoint Therapeutics For further details see: Checkpoin...

Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 Recent publication of cosibelimab pivotal trial results in the Journal for ImmunoTherapy of Cancer WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, In...

Cosibelimab is the first PD-L1–blocking antibody to demonstrate a robust, durable and clinically meaningful objective response, and a manageable safety profile, in patients with metastatic cutaneous squamous cell carcinoma Biologics License Application review ongoing; PDUFA goal ...